Study aims to predict diabetes risk from common transplant drug

NCT ID NCT03640026

Terminated Knowledge-focused Sponsor: Centre Hospitalier Departemental Vendee Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how the drug tacrolimus, often used after kidney transplants, affects blood sugar and insulin in people with kidney failure who are waiting for a transplant. Researchers wanted to find early signs of diabetes risk so doctors could adjust treatment. The study was terminated early and involved 61 adults on hemodialysis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tacrolimus
What this could lead to: If successful, this could help doctors identify patients at risk for tacrolimus-induced diabetes before kidney transplant, allowing them to choose safer immunosuppressants.
What could go wrong: This was a small, terminated Phase 4 study with only 61 participants. Results may not be conclusive or widely applicable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY FAILURE, CHRONIC

Contacts and locations

Locations

Centre Hospitalier Départemental Vendée

La Roche-sur-Yon, France
Centre Hospitalier Universitaire Nantes

Nantes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.